Robert Dingman

Robert Dingman

Auto-generated profile, based on publicly available information

Robert Dingman

Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
LBLisa A. Beck
Lisa A. Beck
RBRobert Bissonnette
Robert Bissonnette
MDMette Deleuran
Mette Deleuran
TNTakeshi Nakahara
Takeshi Nakahara
RGRyszard Galus
Ryszard Galus
ASArsalan Shabbir
Arsalan Shabbir
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent eczematous lesions and sustained pruritus.1 Due to its chronic and recurrent nature, patients with moderate to severe AD usually require long-term treatment. However, many available AD treatments, including high-potency topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), systemic corticosteroids (SCSs), systemic immunosuppressants, and UV therapy, are typically not recommended for long-term use due to concerns around safety or lack of efficacy data.2 Janus kinase inhibitors, which are also approved to treat moderate to severe AD, carry an increased risk of infections and cardiovascular events.3

6 June 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
RDRobert Dingman
Robert Dingman
SBSébastien Bihorel
Sébastien Bihorel
VGViktoria Gusarova
Viktoria Gusarova
JMJeanne Mendell
Jeanne Mendell
RPRobert Pordy
Robert Pordy
Homozygous familial hypercholesterolemia (HoFH) is a rare and serious genetic condition characterized by premature cardiovascular disease due to severely elevated low‐density lipoprotein cholesterol (LDL‐C). HoFH primarily results from loss‐of‐function (LOF) mutations in the LDL receptor (LDLR), reducing LDL‐C clearance such that patients experience severe hypercholesterolemia, exacerbating the risk of developing cardiovascular events. Treatment options such as statins, lomitapide, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and apheresis help lower LDL‐C; however, many patients with HoFH still fail to reach their target LDL‐C levels and many of these lipid‐lowering therapies are not indicated for pediatric use. Angiopoietin‐like protein 3 (ANGPTL3) has been identified as a target to treat elevated LDL‐C by acting as a natural inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes involved in the hydrolysis of the triglyceride and phospholipid content of very low‐density lipoproteins. Persons heterozygous for LOF mutations in ANGPTL3 were reported to have lower LDL‐C than non‐carriers and lower risk of coronary artery disease. Evinacumab is a first‐in‐class human monoclonal antibody that specifically binds to ANGPTL3 to prevent its inhibition of LPL and EL. In clinical trials, a 15 mg/kg intravenous dose every 4 weeks has shown a mean percent change from baseline in LDL‐C of ~50% in adult, adolescent, and pediatric patients with HoFH. This mini review article describes the mechanism of action of evinacumab, evinacumab population PK and PD modeling, and clinical development history of evinacumab for the treatment of HoFH.

17 March 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
SBSébastien Bihorel
Sébastien Bihorel
RDRobert Dingman
Robert Dingman
JMJeanne Mendell
Jeanne Mendell
KNKaty C. Norman
Katy C. Norman
RGRichard T. George
Richard T. George
LHLutz Harnisch
Lutz Harnisch
Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH. Population pharmacometric models characterizing evinacumab exposure and LDL‐C response accounting for lipoprotein apheresis effect in ≥ 5‐year‐old patients were adapted for growth and maturation to predict and compare evinacumab and LDL‐C concentrations across age/weight groups in virtual ≥ 6‐month‐old patients receiving 15 mg/kg evinacumab intravenous (iv) infusions every 4 weeks (q4w). As expected from allometric theory, weight‐based dosing resulted in decreasing evinacumab exposures with declining body weight. Consistent with trends observed in > 5‐year‐old patients, the predicted percent change from LDL‐C baseline (%∆LDL‐C) was generally comparable or even higher in < 5‐year‐old patients (63.0%–68.5%) than in 5‐ to < 18‐year‐old patients (61.3%–67.8%) or adults (51.7%), with the predicted percentages of patients achieving %∆LDL‐C > 50% also higher in < 5‐year‐old patients (82.0%–86.9%) versus 5‐ to < 18‐year‐old patients (72.0%–84.5%) and adults (54.8%). Through a managed access program, six 1‐ to < 5‐year‐old patients received between 5 and 23 iv infusions of 15 mg/kg evinacumab q4w. Rapid and clinically meaningful LDL‐C reductions were observed, with %∆LDL‐C at the last reported dose ranging from 41.3% to 77.3%. Based on the actual patient dosing and plasmapheresis history, model‐predicted evinacumab and LDL‐C concentrations were comparable to the observed data collected in the managed access program. Overall, this analysis provides evidence for the use of evinacumab 15 mg/kg iv q4w dosing regimen in 6‐month‐old to 5‐year‐old patients.

17 March 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
SBSébastien Bihorel
Sébastien Bihorel
RDRobert Dingman
Robert Dingman
JMJeanne Mendell
Jeanne Mendell
YWYuhuan Wang
Yuhuan Wang
PBPoulabi Banerjee
Poulabi Banerjee
LHLutz Harnisch
Lutz Harnisch
Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize evinacumab exposure and LDL‐C response in adolescents and adults. In this analysis, the PK/PD model was refined to include children aged 5 to < 12 years and to characterize the lipoprotein apheresis effect on LDL‐C reduction. The PK of evinacumab was characterized by a two‐compartment model with parallel linear and non‐linear elimination. Linear disposition parameters were allometrically scaled by body weight. Baseline ANGPTL3 concentrations and disease status (non‐HoFH vs. HoFH) influenced the maximum target‐mediated rate of elimination but had a minimal effect on evinacumab exposures at 15 mg/kg intravenous doses every 4 weeks across weight/age groups. In patients with HoFH, the LDL‐C reduction was adequately described by an indirect response model in which evinacumab inhibits the formation of LDL‐C and that includes a secondary elimination process quantifying the lipoprotein apheresis effect. Older age was associated with a decrease in baseline LDL‐C. An increase in body weight was associated with a reduction in the maximum inhibitory effect of evinacumab. Model‐based simulations showed that while evinacumab exposure is reduced with decreasing age/body weight, younger patients are predicted to have a comparable or greater magnitude of LDL‐C reduction than older patients at a dose of 15 mg/kg. Overall, the model adequately predicted the evinacumab exposure and LDL‐C reduction in children, adolescents, and adults with HoFH, aligning with clinically relevant observations.